Vertex Pharmaceuticals (VRTX) Total Debt (2009 - 2017)

Vertex Pharmaceuticals has reported Total Debt for 7 years, with the latest figure at $232.4 million in Q4 2017.

• On a quarterly basis, Total Debt fell 37.76% year-over-year to $232.4 million in Q4 2017; TTM through Dec 2017 was $232.4 million, a 37.76% decrease from a year earlier, with the FY2017 full-year figure at $232.4 million, down 37.76% from the prior year.
• Total Debt was $232.4 million for Q4 2017 at Vertex Pharmaceuticals, up from $190.3 million in the prior quarter.
• The five-year high for Total Debt was $373.4 million in Q4 2016, with the low at $104.8 million in Q1 2017.
• Average Total Debt over 4 years is $264.8 million, with a median of $294.8 million recorded in 2015.
• The sharpest annual moves came in 2016 and 2017: Total Debt climbed 26.51% in 2016, then plunged 64.58% in 2017.
• Over 4 years, Total Debt stood at $294.8 million in 2014, then rose by 0.13% to $295.2 million in 2015, then climbed by 26.51% to $373.4 million in 2016, then slumped by 37.76% to $232.4 million in 2017.
• The last three Total Debt figures came in at $232.4 million (Q4 2017), $190.3 million (Q3 2017), and $147.7 million (Q2 2017), per Business Quant data.